TARGET AUDIENCE
This activity has been designed to meet the educational needs of medical and radiation oncologists, urologists and other allied healthcare professionals.

OVERVIEW OF ACTIVITY
Cancers of the genitourinary system affect hundreds of thousands of individuals within the United States each year, accounting for almost 30% of all newly diagnosed human cancers. Tumors of the prostate are definitively the most prevalent and are therefore the topic of extensive ongoing clinical research. Consequently, the clinical management of prostate cancer (PC) is frequently in a state of evolution, necessitating rapid and consistent clinician access to emerging data sets of relevance to the continuous delivery of quality cross-functional care.

These video proceedings from a CME symposium held during the 2014 Genitourinary Cancers Symposium feature discussions with leading prostate cancer investigators regarding actual patient cases and related clinical research findings. By providing information on the latest research developments in the context of expert perspectives, this activity will assist medical and radiation oncologists, urologists and other healthcare professionals with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with PC.

LEARNING OBJECTIVES

• Recall existing and emerging research information demonstrating the effects of secondary hormonal interventions on quality and quantity of life for patients with chemotherapy-naïve or pretreated castration-resistant PC (CRPC), and use this information to guide treatment planning for these patients.
• Effectively apply evidence-based research findings in the administration of available immunotherapeutic, chemotherapeutic and secondary hormonal agents, alone or in combination, for patients with metastatic PC.
• Consider available Phase III clinical trial data documenting the efficacy of radium-223 dichloride in patients with PC and bone metastases, and formulate strategies to appropriately use this recently approved radiopharmaceutical agent.
• Assess available clinical and laboratory research evidence evaluating the impact of prior endocrine therapy exposure on the responsiveness of metastatic CRPC to cytotoxic interventions.
• Explore the emerging data and active research evaluating novel agents in the setting of PSA-only recurrent or advanced PC, and discuss the biologic basis for their clinical activity.
• Counsel appropriately selected patients with biochemically recurrent, asymptomatic and symptomatic metastatic PC about availability of and participation in ongoing clinical trials.

ACCREDITATION STATEMENT

CME credit is no longer available for this issue

CREDIT DESIGNATION STATEMENT

CME credit is no longer available for this issue

HOW TO USE THIS CME ACTIVITY
This CME activity consists of a video component. The participant should watch the video.

CME credit is no longer available for this issue

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

Tomasz M Beer, MD
Grover C Bagby Endowed Chair for Prostate Cancer Research
Professor of Medicine, Hematology and Medical Oncology
Deputy Director, OHSU Knight Cancer Institute
Portland, Oregon

Consulting Agreement: Dendreon Corporation; Contracted Research: Astellas, Bristol-Myers Squibb Company, Cougar Biotechnology Inc, Dendreon Corporation, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Janssen Biotech Inc, Medivation Inc, Novartis Pharmaceuticals Corporation, OncoGenex Pharmaceuticals Inc.

Susan F Slovin, MD, PhD
Attending Physician
Genitourinary Oncology Service
Sidney Kimmel Center for Prostate and Urologic Cancers
Memorial Sloan-Kettering Cancer Center
Professor of Medicine
Weill-Cornell Medical College
New York, New York

Contracted Research: Astellas, Sanofi.

A Oliver Sartor, MD
Medical Director, Tulane Cancer Center
Laborde Professor of Cancer Research
Professor of Medicine and Urology
Tulane Medical School
New Orleans, Louisiana

Advisory Committee: Bayer HealthCare Pharmaceuticals, Sanofi; Consulting Agreements: Algeta ASA, Bavarian Nordic, Bayer HealthCare Pharmaceuticals, Biscayne Pharmaceuticals Inc, Medivation Inc, OncoGenex Pharmaceuticals Inc, Sanofi; Contracted Research: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Millennium: The Takeda Oncology Company, Progenics Pharmaceuticals Inc, Sanofi.

William K Oh, MD
Chief, Division of Hematology and Medical Oncology
Professor of Medicine and Urology
Ezra M Greenspan, MD Professor in Clinical Cancer Therapeutics
Mount Sinai School of Medicine
Associate Director of Clinical Research
The Tisch Cancer Institute
New York, New York

Advisory Committee: Amgen Inc, Astellas, Bayer HealthCare Pharmaceuticals, Dendreon Corporation, Janssen Pharmaceuticals Inc, Medivation Inc.

David I Quinn, MBBS, PhD
Medical Director, Norris Cancer Hospital and Clinics
Leader, Developmental Therapeutics
Head, GU Cancer Section
Division of Cancer Medicine and Blood Diseases
USC/Norris Comprehensive Cancer Center
Los Angeles, California

Advisory Committee: Amgen Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Dendreon Corporation, Genentech BioOncology, Janssen Pharmaceuticals Inc, Medivation Inc, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Pfizer Inc, Prometheus Laboratories Inc, Teva Oncology, Veridex LLC; Paid Research: Millennium: The Takeda Oncology Company, Sanofi; Other Remunerated Activities: Medivation Inc, Teva Oncology.

CONSULTING MEDICAL ONCOLOGISTS — The following consulting medical oncologists (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

Paul AS Fishkin, MD
Illinois CancerCare
Peoria, Illinois

Common Stock: Johnson & Johnson Pharmaceuticals, Novartis Pharmaceuticals
Corporation.

Philip T Glynn, MD
Director, Medical Oncology
Mercy Medical Center
Director of Oncology
Noble Hospital
Assistant Clinical Professor
Tufts University School of Medicine
Springfield, Massachusetts

No real or apparent conflicts of interest to disclose.

Carl T Henningson Jr, MD
Regional Cancer Care Associates
Freehold, New Jersey

Speakers Bureau: Astellas, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, Medivation Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Algeta US, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc, Teva Oncology and VisionGate Inc.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Algeta US/Bayer HealthCare Pharmaceuticals, Astellas/Medivation Inc, Exelixis Inc, Millennium: The Takeda Oncology Company, Sanofi and Teva Oncology.

Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Last review date: May 2014
Expiration date: May 2015

CME credit is no longer available for this issue